Hepatocellular carcinoma (HCC) is one of the most common malignant tumors
worldwide, with nearly one million new cases and deaths every year. Owing to the complex
pathogenesis, hidden early symptoms, rapidly developing processes, and poor prognosis, the
morbidity and mortality of HCC are increasing yearly. With the progress being made in modern
medicine, the treatment of HCC is no longer limited to traditional methods. Targeted therapy
and immunotherapy have emerged to treat advanced and metastatic HCC in recent years.
Since Sorafenib is the first molecular targeting drug against angiogenesis, targeted drugs for
HCC are continually emerging. Moreover, immunotherapy plays a vital role in clinical trials.
In particular, the application of immune checkpoint inhibitors, which have received increasing
attention in the field of cancer treatment, is a possible research path. Interestingly, these two
therapies generally complement each other at some stages of HCC, bringing new hope for patients
with advanced HCC. In this paper, we discuss the research progress of targeted therapy
and immunotherapy for HCC in recent years, which will provide a reference for the further
development of drugs for HCC.